NEOSTIGMINE METHYLSULFATE | N203629 | FRESENIUS KABI USA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Lachman Consulting Services Inc FDA-2021-P-0277 Lachman Consulting Services Inc. filed this suitability petition under Section 505(j)(2)(C) of the FD&C Act requesting that the FDA declare Neostigmine Methylsulfate Injection in three new strengths (5 mg/5 mL, 1.5 mg/3 mL, and 2.5 mg/5 mL single-dose prefilled syringes) suitable for submission as a | Suitability | 2021-03-09 | Open | Lachman Consulting Services Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.